Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 22635030)

1.

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.

Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J.

Int J Gynecol Cancer. 2012 Jun;22(5):807-11. doi: 10.1097/IGC.0b013e31824a33a2.

2.
3.
4.

Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.

Crespo G, Sierra M, Losa R, Berros JP, Villanueva N, Fra J, Fonseca PJ, Luque M, Fernández Y, Blay P, Sanmamed M, Muriel C, Esteban E, Lacave AJ.

Int J Gynecol Cancer. 2011 Apr;21(3):478-85. doi: 10.1097/IGC.0b013e31820d738c.

PMID:
21436695
5.

Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.

Vandenput I, Vergote I, Neven P, Amant F.

Int J Gynecol Cancer. 2012 May;22(4):617-22. doi: 10.1097/IGC.0b013e31824a3385.

PMID:
22426408
6.
7.

Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.

Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T.

Asian Pac J Cancer Prev. 2013;14(4):2421-7.

8.

Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.

Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, Atlas I, Levy T, Rosengarten OS.

Int J Gynecol Cancer. 2013 Mar;23(3):475-80. doi: 10.1097/IGC.0b013e3182866944.

PMID:
23435437
9.

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.

Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I.

Neoplasma. 2009;56(4):291-7.

PMID:
19473054
10.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

PMID:
24978709
11.

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.

Safra T, Ron I, Boaz M, Brenner J, Grisaru D, Inbar M, Hayat H, Menczer J, Golan A, Levy T.

Acta Oncol. 2006;45(4):463-8.

PMID:
16760183
12.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
13.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
14.

Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.

Yuan SF, Zhang LP, Zhu LJ, Chen WJ, Zheng WE, Xiong JP.

Asian Pac J Cancer Prev. 2013;14(6):3949-53.

15.

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.

Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a.

PMID:
22635029
16.

Detection of recurrence in a surveillance program for epithelial ovarian cancer.

Suprasert P, Chalapati W.

Asian Pac J Cancer Prev. 2013;14(12):7193-6.

17.

Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.

Kuku S, Williams M, McCormack M.

Int J Gynecol Cancer. 2013 Jul;23(6):1056-64. doi: 10.1097/IGC.0b013e3182978328.

PMID:
23765205
18.

Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.

Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.

Int J Gynecol Cancer. 2013 Mar;23(3):461-8. doi: 10.1097/IGC.0b013e318286665b.

PMID:
23370604
19.

A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.

Al-Badawi IA, Munkarah AR, Tulbah A, Babic II, Al Husaini H, Ahmad S.

Int J Gynecol Cancer. 2013 Mar;23(3):456-60. doi: 10.1097/IGC.0b013e318284aafe.

PMID:
23360812
20.

The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.

Peled Y, Levavi H, Krissi H, Weill Y, Sabah G, Eitan R.

Am J Clin Oncol. 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399.

PMID:
22706176
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk